WO2005049003A1 - Formes pharmaceutiques a liberation prolongee de chlorhydrate de bupropion - Google Patents

Formes pharmaceutiques a liberation prolongee de chlorhydrate de bupropion Download PDF

Info

Publication number
WO2005049003A1
WO2005049003A1 PCT/IB2004/003778 IB2004003778W WO2005049003A1 WO 2005049003 A1 WO2005049003 A1 WO 2005049003A1 IB 2004003778 W IB2004003778 W IB 2004003778W WO 2005049003 A1 WO2005049003 A1 WO 2005049003A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
extended release
release dosage
core
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2004/003778
Other languages
English (en)
Inventor
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to EP04798903A priority Critical patent/EP1686974A1/fr
Publication of WO2005049003A1 publication Critical patent/WO2005049003A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Definitions

  • the present invention relates to extended release dosage forms of bupropion hydrochloride and processes for their preparation.
  • Bupropion hydrochloride is a well-known antidepressant and non-nicotine aid to smoking cessation. It has been observed that bupropion hydrochloride when taken in an immediate release dosage form has the risk of inducing seizures in patients. This side effect is attributed to the sudden high peak plasma concentration produced by these immediate release dosage forms. The incidences of seizures can be subsided by designing a dosage form of bupropion hydrochloride with extended release properties so that sudden high peak plasma concentration is avoided.
  • 4,687,660 discloses a controlled release dosage form powered by an osmotic pumping mechanism.
  • the dosage form comprises a core containing bupropion hydrochloride and osmotic enhancing agent in an amount equal to or greater than bupropion hydrochloride.
  • the core is coated with a semi-permeable polymeric film consisting of water insoluble, water permeable polymer, channeling agents which dissolve in the gastrointestinal fluids and provide passage for the release of drug from the core.
  • the drug release from the core is driven by osmotic pressure.
  • This type of dosage form has the disadvantage that there is always a risk of dose dumping in case too much pressure is built up in the core and the dosage form may burst releasing the entire drug at once which may also precipitate a seizure.
  • an extended release dosage form of bupropion hydrochloride includes a core, and a coating on the core.
  • the core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents.
  • the coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients.
  • Embodiments of the dosage form may include one or more of the following features.
  • a seal coating may be included between the core and the coating surrounding the core.
  • the seal coating may include one or more water soluble polymers for example, hydroxypropylmethylcellulose and hydroxypropylcellulose.
  • the one or more pharmaceutically acceptable excipients may include one or more binders, fillers, plasticizers, and lubricants /glidants.
  • the binders may include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof.
  • the fillers may be microcrystalline cellulose.
  • the lubricants may include one or more of magnesium stearate, stearic acid, and glyceryl behenate.
  • the plasticizers may include one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1,2-propyleneglycol, dibutylsebacate, diethylsebacate, and mixtures thereof.
  • the coating on the core may include one or more polymers that may be permeable to gastrointestinal fluids but insoluble in the same.
  • polymers include cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like.
  • an enteric coating may be applied outside the coating surrounding the core.
  • the enteric coating may include one or more enterosoluble polymers.
  • the enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine.
  • the enteric layer may serve to protect the drug from gastric contents.
  • enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
  • the coatings may optionally contain one or more excipients such as plasticizers, lubricants, glidant anti-adherents for example, magnesium stearate, talc, colloidal silicon dioxide, silicon dioxide, inert fillers, and pigments. Silicon dioxide may additionally function as a wicking agent for fluids from the external media into the core.
  • an extended release dosage form of bupropion hydrochloride includes a core, a first coating on the core and a second enteric coating surrounding the first coating.
  • the core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents.
  • the first coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients.
  • the second enteric coating surrounds the first coating and includes one or more enterosoluble polymers and, optionally, one or more pharmaceutically acceptable excipients.
  • Embodiments of the dosage form may include one or more of the following features.
  • a seal coating may be included between the core and the first coating surrounding the core.
  • the seal coating may include one or more water soluble polymers for example, hydroxypropylmethylcellulose and hydroxypropylcellulose.
  • the one or more pharmaceutically acceptable excipients may include one or more binders, fillers, plasticizers, and lubricants /glidants.
  • the binders may include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof.
  • the fillers may be microcrystalline cellulose.
  • the lubricants may include one or more of magnesium stearate, stearic acid, and glyceryl behenate.
  • the plasticizers may include one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1 ,2-propyleneglycol, dibutylsebacate, diethylsebacate, and mixtures thereof.
  • the coating on the core may include one or more polymers that may be permeable to gastrointestinal fluids but insoluble in the same.
  • polymers include cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like.
  • the enteric coating may include one or more enterosoluble polymers.
  • the enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine.
  • the enteric layer may serve to protect the drug from gastric contents.
  • enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
  • the coatings may optionally contain one or more excipients such as plasticizers, lubricants, glidant anti-adherents for example, magnesium stearate, talc, colloidal silicon dioxide, silicon dioxide, inert fillers, and pigments.
  • Silicon dioxide may additionally function as a wicking agent for fluids from the external media into the core.
  • a process for the preparation of extended release dosage forms of bupropion hydrochloride includes preparing a core, and coating the core with a layer. The process also includes optionally coating the core with a seal coat and/or the coating surrounding the core with an enteric layer.
  • the core may be prepared by granulating bupropion hydrochloride, and, optionally mixing with one or more pharmaceutically acceptable excipients and compressing.
  • the core may be coated with a layer formed by a substantially water- insoluble film forming polymers, channeling agents and, optionally, pharmaceutically acceptable excipients.
  • a method of treating depression or nicotine addiction includes administering an extended release dosage form that includes a core, and a coating on the core.
  • the core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents.
  • the coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients.
  • the dosage form may include a seal coating which may be applied between the core and the coating surrounding the core.
  • the seal coating may include one or more water soluble polymers like hydroxypropylmethylcellulose and hydroxypropylcellulose.
  • the enteric coating may include one or more enterosoluble polymers.
  • the details of various embodiments of the inventions are set forth in the accompanying description below. Other features and advantages of the inventions will be apparent from the description and the claims. Detailed Description of the Invention As described in detail herein, the inventors have discovered that extended release dosage forms of bupropion hydrochloride may be formulated without the need for osmotic enhancing agents. For example, the inventors have developed an extended release dosage form that includes a core, and a coating on the core. The core includes bupropion hydrochloride and, optionally pharmaceutically acceptable excipients. The core is characterized as being free of osmotic enhancing agents.
  • the core is coated with a layer that includes water-insoluble film forming polymers and, optionally, one or more pharmaceutically acceptable excipients.
  • a seal coating may be applied between the core and the coating surrounding the core.
  • the inventors also have developed an extended release dosage form that includes a core, a first coating on the core and a second enteric coating surrounding the first coating.
  • the core includes bupropion hydrochloride and, optionally pharmaceutically acceptable excipients.
  • the core is characterized as being free of osmotic enhancing agents.
  • a seal coating may be applied between the core and the first coating surrounding the core.
  • the core containing bupropion hydrochloride can be prepared by either directly compressing, wet granulating or dry granulating a mixture of bupropion hydrochloride and other excipients like binders, fillers and lubricants/glidants.
  • One process to formulate the extended release dosage form includes preparing a core and coating the core. To prepare the core, bupropion hydrochloride and, optionally one or more pharmaceutically acceptable excipients are dispersed in purified water, one or more solvents, or mixtures thereof to obtain dispersion. The dispersion is spray dried, mixed with optional pharmaceutically acceptable excipients, and compressed to form cores.
  • the core then is coated with a layer that is formed from substantially water- insoluble film forming polymers and optional pharmaceutically acceptable excipients.
  • the coated core then may be coated with an enteric coating.
  • the core may also be coated with a seal coating between the core and the coating surrounding the core.
  • the amount of bupropion hydrochloride may vary from about 5 mg to about
  • the core as used herein refers to any structure that is enclosed or surrounded by a coating or equivalent.
  • the core may be in the form of a tablet, pellet, or mixture thereof.
  • the term 'pellets' as used herein may include one or more of granules, beads, pellets, slugs or mixtures thereof.
  • the core may contain one or more pharmaceutically acceptable excipients, including one or more of binders, fillers, and lubricants/glidants. Suitable binders include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof.
  • Suitable fillers include microcrystalline cellulose.
  • Suitable lubricants include one or more of magnesium stearate, stearic acid, and glyceryl behenate.
  • the preferred range of lubricants in the formulation depends on the type of formulations to be prepared as disclosed in various examples contained herein.
  • the various coating layers can then be applied on the compressed core by conventional coating techniques like spray drying, pan coating, etc. well known to a person skilled in the art.
  • the solvents used in preparing solution or dispersion of coating compositions can be aqueous or organic or a mixture of both.
  • the suitable solvents include water, dichlorom ethane, isopropyl alcohol, methanol, acetone, and mixtures of isopropyl alcohol with dichloromethane or water.
  • the solvent system used in preparing water insoluble coating containing channeling agents is prepared in organic solvent in which channeling agent is insoluble such as acetone, dichloromethane, isopropyl alcohol and mixtures thereof.
  • the coating surrounding the core is made up of substantially water-insoluble film forming polymers, channeling agents and, optionally, plasticizers.
  • the coating may contain one or more pharmaceutically acceptable excipients.
  • the substantially water- insoluble film forming polymers may be selected from cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like.
  • the drug may be released from the core due to the presence of water-soluble channeling agents in the coating, which upon dissolution may form a porous membrane through which the drug could diffuse out.
  • channeling agents examples include lactose, sucrose, sorbitol, mannitol, sodium chloride, calcium chloride, potassium chloride, and the like.
  • the range of the channeling agents in the formulations depends on the type of formulations prepared and will be apparent to one skilled in the art based on the various examples disclosed in the specification.
  • the coating surrounding the core may be coated with a layer containing enterosoluble polymers.
  • the enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine.
  • the enteric layer may serve to protect the drug from gastric contents.
  • enteric polymers examples include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
  • the extended release dosage form is capable of delivering bupropion hydrochloride at a predictable rate.
  • the dosage form may maintain therapeutic plasma levels of bupropion from about 12 to 24 hours. Accordingly, the dosage form may be designed to be given once or twice daily.
  • Bupropion hydrochloride was granulated with an aqueous solution of polyvinyl alcohol in a fluidized bed granulator. The granules were dried and sized. The sized granules were lubricated with magnesium stearate, glyceryl behenate and colloidal silicon dioxide and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylmethylcellulose and triethyl citrate dissolved in purified water was applied to the compressed cores as a seal coating.
  • coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: water (95:5) mixture. Finally, these coated cores were coated with an enteric coating dispersion containing Eudragit L30 D 55, triethyl citrate, silicon dioxide and polyethylene glycol dispersed in purified water.
  • Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose and triethyl citrate in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • the coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, lactose monohydrate and hydroxypropylmethylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
  • Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • the coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, lactose monohydrate and hydroxypropylmethylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
  • Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate, lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
  • Bupropion hydrochloride was granulated with hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylmethylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate, lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: water mixture (95:5). Finally, these coated cores were coated with an enteric coating dispersion containing Eudragit L30 D 55, triethyl citrate, silicon dioxide and polyethylene glycol dispersed in purified water.
  • Example 6 Dissolution profiles of tablets of examples 1-5 as measured in a USP type I dissolution apparatus, at 75 rpm, at a temperature of 37 ⁇ 0.5°C in 900ml of 0.01N hydrochloric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formes pharmaceutiques à libération prolongée de chlorhydrate de bupropion et leurs procédés de préparation. Cette forme pharmaceutique comporte un noyau revêtu d'un enrobage. Ce noyau contient du chlorhydrate de bupropion et, éventuellement, un ou plusieurs excipients pharmaceutiquement acceptables, ledit noyau étant dépourvu d'agents stimulants osmotiques. L'enrobage entoure le noyau et renferme un ou plusieurs polymères filmogènes hydro-insolubles, des agents d'acheminement et, éventuellement, un ou plusieurs excipients pharmaceutiquement acceptables.
PCT/IB2004/003778 2003-11-21 2004-11-18 Formes pharmaceutiques a liberation prolongee de chlorhydrate de bupropion WO2005049003A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04798903A EP1686974A1 (fr) 2003-11-21 2004-11-18 Formes pharmaceutiques a liberation prolongee de chlorhydrate de bupropion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1449/DEL/2003 2003-11-21
IN1449DE2003 2003-11-21

Publications (1)

Publication Number Publication Date
WO2005049003A1 true WO2005049003A1 (fr) 2005-06-02

Family

ID=34611193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003778 WO2005049003A1 (fr) 2003-11-21 2004-11-18 Formes pharmaceutiques a liberation prolongee de chlorhydrate de bupropion

Country Status (2)

Country Link
EP (1) EP1686974A1 (fr)
WO (1) WO2005049003A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060540A1 (fr) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Formes galéniques stables d'un antidépresseur
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687660A (en) * 1983-08-16 1987-08-18 Burroughs Wellcome Co. Pharmaceutical delivery system
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
WO2003086362A2 (fr) * 2002-04-15 2003-10-23 Ranbaxy Laboratories Limited Comprimes d'hydrochlorure de bupropion stables

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687660A (en) * 1983-08-16 1987-08-18 Burroughs Wellcome Co. Pharmaceutical delivery system
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
WO2003086362A2 (fr) * 2002-04-15 2003-10-23 Ranbaxy Laboratories Limited Comprimes d'hydrochlorure de bupropion stables

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060540A1 (fr) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Formes galéniques stables d'un antidépresseur
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Also Published As

Publication number Publication date
EP1686974A1 (fr) 2006-08-09

Similar Documents

Publication Publication Date Title
JP6457458B2 (ja) 時限パルス放出システム
AU2002248792B2 (en) A novel coating for a sustained release pharmaceutical composition
CA2349696C (fr) Formulation a liberation regulee pour medicaments solubles a l'eau
CA2514879C (fr) Utilisation d'un melange de deux ou de plusieurs matieres d'enrobage enteriques afin de reguler la liberation de medicaments
US5830503A (en) Enteric coated diltiazem once-a-day formulation
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
AU2002248792A1 (en) A novel coating for a sustained release pharmaceutical composition
JPH072645A (ja) ｐＨ作動性浸透破裂放出用製剤
WO2007036952A2 (fr) Nouvelle forme posologique a liberation soutenue
KR100591142B1 (ko) 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
JP2014208655A (ja) 持続放出性剤形
JP4540092B2 (ja) 酸に不安定な生理活性化合物を含有する製剤組成物及びその製法
WO2009069089A9 (fr) Composition de lévétiracétam à libération contrôlée de
WO2001080824A2 (fr) Formes de dosage a liberation a modifiee a double mecanisme pour medicaments faiblement doses
WO2008023390A2 (fr) Composition pharmaceutique de chlorhydrate de bupropion à libération modifiée
CA2409721A1 (fr) Une composition de pellicule pour faciliter la liberation regulee
JPH09504779A (ja) α−アドレノリセプタ遮断剤用薬剤移送組成物
CA2685214C (fr) Forme posologique orale a liberation regulee amelioree
WO2005049003A1 (fr) Formes pharmaceutiques a liberation prolongee de chlorhydrate de bupropion
US20090186087A1 (en) Enteric sustained-release coated core and pharmaceutical dosage form and method for manufacturing the same
JP2018184360A (ja) 経口投与用の腸溶性徐放性製剤
AU2014246617A1 (en) Multi-layered, multiple unit pharmaceutical compositions
AU2002253907A1 (en) Improved controlled release oral dosage form

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE